Journal: The Tohoku journal of experimental medicine

Article Title: Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

doi: 10.1620/tjem.241.239

Figure Lengend Snippet: Fig. 1. Expression of TBL1XR1 in serous EOC tissues. (A) Representative high expression of TBL1XR1 in EOC tissues, with the IHC score 9. (B) Representative low expres- sion of TBL1XR1 in EOC tissues, with the IHC score 0. (C) Western blot analysis showed the protein levels of TBL1XR1 in 8 pairs of EOC tissues (T) and adjacent non-tumorous tissues (ANT). (D) Quantification of the protein levels of TBL1XR1 with Graphpad prism 5.0 software. (E) RT-qPCR results demonstrated that the mRNA level of TBL1XR1 was higher in tumor tissues than that in adjacent non-tumorous tissues (n = 8). Magnification: 200X.

Article Snippet: The Myc-tagged human TBL1XR1 cDNA was obtained from Origene (NM_024665) and cloned into pcDNA3.0 vector for trans- fection.

Techniques: Expressing, Western Blot, Software, Quantitative RT-PCR

Journal: The Tohoku journal of experimental medicine

Article Title: Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

doi: 10.1620/tjem.241.239

Figure Lengend Snippet: Fig. 2. Correlations between TBL1XR1 and clinical characteristics of serous EOC patients. (A) EOC patients with advanced FIGO stages showed higher immunoreactivity of TBL1XR1 (P = 0.009). (B) Expres- sion levels of TBL1XR1 were higher in patients with positive lymph node metastasis than in those with negative lymph node metastasis (P = 0.002). (C) Kaplan-Meier survival curve showed that higher expression of TBL1XR1 was corre- lated with poorer overall survival of EOC patients. (D) The VEGF-C mRNA levels were positively correlated with TBL1XR1 mRNA expression in tumor tissues (The data was generated by RT-qPCR from 8 paired EOC tissues and adjacent non-tumorous tissues. X axis showed the fold changes of TBL1XR1 while Y axis showed the fold changes of VEGF-C in corresponding tissues).

Article Snippet: The Myc-tagged human TBL1XR1 cDNA was obtained from Origene (NM_024665) and cloned into pcDNA3.0 vector for trans- fection.

Techniques: Expressing, Generated, Quantitative RT-PCR

Journal: The Tohoku journal of experimental medicine

Article Title: Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

doi: 10.1620/tjem.241.239

Figure Lengend Snippet: Fig. 3. TBL1XR1 modulates the expression of VEGF-C in EOC cells. TBL1XR1 showed highest protein expression in OVCAR3 cells among Hs832, SKOV3, and OVCAR3 cell lines, whereas no signifi- cant difference was observed between Hs832 and SKOV3 cells (A, B). TBL1XR1 overexpression increased the protein level of VEGF-C (C, D). In contrast, TBL1XR1 silencing by siRNAs down-regulated the protein expression of VEGF-C (E, F). Each experi- ment was performed in triplicate.

Article Snippet: The Myc-tagged human TBL1XR1 cDNA was obtained from Origene (NM_024665) and cloned into pcDNA3.0 vector for trans- fection.

Techniques: Expressing, Over Expression

Journal: The Tohoku journal of experimental medicine

Article Title: Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

doi: 10.1620/tjem.241.239

Figure Lengend Snippet: Fig. 4. Role of TBL1XR1 in regulating proliferation and invasion of EOC cells. TBL1XR1 overexpression enhanced the proliferation ability of SKOV3 cells (A), and TBL1XR1 knock-down impaired the viability of OVCAR3 cells (B). Similarly, the invasion capacity of EOC cells was also positively correlated with the TBL1XR1 expression levels (C, D). Each experiment was performed in triplicate.

Article Snippet: The Myc-tagged human TBL1XR1 cDNA was obtained from Origene (NM_024665) and cloned into pcDNA3.0 vector for trans- fection.

Techniques: Over Expression, Knockdown, Expressing

Journal: iScience

Article Title: Elabela inhibits TRAF1/NF-κB induced oxidative DNA damage to promote diabetic foot ulcer wound healing

doi: 10.1016/j.isci.2023.107601

Figure Lengend Snippet:

Article Snippet: rabbit anti-p21 , Proteintech , Cat# 10335-1-AP.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Plasmid Preparation, Software, Extraction

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: X-ray diffraction patterns for ( A ) iron oxide nanoparticles; ( B ) MLDH; ( C ) pure sorafenib; ( D ) pure PEG; ( E ) core–shell nanoparticles (FPEGSO-MLDH); ( F ) pure PVA; ( G ) core–shell nanoparticles (FPVASO-MLDH). Inset shows the XRD patterns of ( H ) FPEGSO and ( I ) FPVASO.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques:

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Fourier transform infrared spectra for ( A ) iron oxide nanoparticles; ( B ) MLDH; ( C ) pure sorafenib; ( D ) pure PVA; ( E ) core–shell nanoparticles (FPVASO-MLDH); ( F ) pure PEG; ( G ) core–shell nanoparticles (FPEGSO-MLDH). Inset shows the FTIR spectra of ( H ) FPEGSO and ( I ) FPVASO.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques:

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Release profiles of sorafenib from its physical mixtures ( A ) FPEGSO-MLDH; ( B ) FPVASO-MLDH in phosphate-buffered solution at pH 4.8; ( C ) FPEGSO-MLDH; ( D ) FPVASO-MLDH in phosphate-buffered solution at pH 7.4.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques:

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Sorafenib release profiles from ( A ) FPEGSO-MLDH; ( B ) FPVASO-MLDH in phosphate-buffered solution at pH 4.8; ( C ) FPEGSO-MLDH; ( D ) FPVASO-MLDH in phosphate-buffered solution at pH 7.4.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques:

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: The correlation coefficient, rate constant and half-life obtained by fitting the sorafenib release data into the PBS solution at pH 4.8 and pH 7.4.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques: Diffusion-based Assay

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Fitting the data for sorafenib release from ( A ) FPEGSO-MLDH nanoparticles; ( B ) FPVASO-MLDH nanoparticles dissolved in dimethyl sulfoxide into different solutions to the pseudo-second-order kinetics for pH 7.4; ( C ) FPEGSO-MLDH nanoparticles; ( D ) FPVASO-MLDH nanoparticles dissolved in dimethyl sulfoxide into different solutions to the pseudo-second-order kinetics for pH 4.8. Abbreviations: t, time; q t , release at time t.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques:

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Cytotoxicity assay of Sorafenib (SO), FPEG-MLDH, FPVA-MLDH, FPEGSO-MLDH and FPVASO-MLDH against normal 3T3 cells at 72 h. Results were calculated as mean ± standard deviation for n = 3 independent experiments. * p < 0.05 compared to control (untreated cells) and treatment group using the ANOVA and Duncan’s Multiple Range Test.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques: Cytotoxicity Assay, Standard Deviation

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: Cytotoxicity assay of sorafenib (SO), FPEG-MLDH, FPVA-MLDH, FPEGSO-MLDH and FPVASO-MLDH against HepG2 cells at 72 h of incubation. Results were calculated as mean ± standard deviation for n = 3 independent experiments. * p < 0.05 compared to control (untreated cells) and treatment group using the ANOVA and Duncan’s Multiple Range Test.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques: Cytotoxicity Assay, Incubation, Standard Deviation

Journal: Scientific Reports

Article Title: Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications

doi: 10.1038/s41598-020-76504-5

Figure Lengend Snippet: The half-maximal inhibitory concentration (IC 50 ) value for sorafenib (SO), FPEG-MLDH, FPVA-MLDH, FPEGSO-MLDH, and FPVASO-MLDH samples tested on 3T3 and HepG2 cell lines.

Article Snippet: Sorafenib (C 21 H 16 ClF 3 N 4 O 3 ) was sourced from Xi'an Yiyang Bio-Tech (China) at 98.5% purity.

Techniques: Concentration Assay

Journal: Toxins

Article Title: Host Genotype and Weather Effects on Fusarium Head Blight Severity and Mycotoxin Load in Spring Barley

doi: 10.3390/toxins14020125

Figure Lengend Snippet: Genotype ranking according to detected Fusarium toxin contents in mature barley heads after bruised grain inoculation in the seasons 2018 to 2020. The heat map represents scored mean ranks according to detected contents of DON, NIV, DON3G, 3ADON, enniatins A, A1, B and B1 in mature barley heads in inoculated sub plots. Mean ranks of individual genotypes and the respective standard error of the mean are presented in the grey shaded box. Low ranks indicate high FHB resistance; high ranks indicate low FHB resistance. Error bars indicate standard error of the mean.

Article Snippet: Unlabelled reference compounds (deoxynivalenol-3-glucoside (D3G), 15-acetyl-deoxynivalenol (15-ADON), T2-toxin) and some labelled standards ( 13 [C 15 ]-DON, 13 [C 17 ]-3-ADON, 13 [C 22 ]-HT2-toxin and 13 [C 21 ]-D3G) were purchased from Biopure (Tulln, Austria).

Techniques: